Table II.
Overall survival by univariate analysis.
| Variable | Months (median) | Hazard ratio (95% CI) | P-value |
|---|---|---|---|
| Age, years | 0.60 | ||
| ≥50 vs. <50 | 55.0 vs. 24.9 | 0.763 (0.273–2.134) | |
| Stage | 0.041 | ||
| IIIA+IIIB vs. IIIC+IV | 55.8 vs. 14.5 | 0.351 (0.124–0.995) | |
| p53 | 0.016 | ||
| Negative vs. positive | 59.6 vs. 24.2 | 0.270 (0.087–0.837) | |
| HER2 | 0.34 | ||
| Negative vs. positive | 54.3 vs. 26.7 | 0.602 (0.212–1.708) | |
| ER | 0.47 | ||
| Positive vs. negative | 45.3 vs. 34.1 | 0.655 (0.207–2.076) | |
| VEGF-A | 0.94 | ||
| High vs. low | 55.4 vs. 31.8 | 0.956 (0.324–2.825) | |
| sVEGF | 0.25 | ||
| High vs. low | 57.0 vs. 26.0 | 0.507 (0.155–1.663) | |
| pVEGFR2-Y951 | 0.39 | ||
| High vs. low | 52.1 vs. 31.8 | 0.601 (0.185–1.955) | |
| MVD | 0.74 | ||
| Low vs. high | 41.8 vs. 38.1 | 0.822 (0.258–2.616) | |
| Ki67 | 0.07 | ||
| Low vs. high | 57.1 vs. 17.3 | 0.344 (0.103–1.150) | |
| Apoptosis | 0.011 | ||
| Low vs. high | 61.5 vs. 20.2 | 0.219 (0.061–0.781) |
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MVD, microvessel density; No., number; pVEGFR2, phosphorylated vascular endothelial growth factor receptor 2; sVEGF, serum vascular endothelial growth factor; VEGF-A, vascular endothelial growth factor A.